Immunovant, Inc.
IMVT
$14.48
-$0.74-4.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.78M | 18.47M | 18.81M | 14.82M | 13.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.30M | 115.74M | 94.28M | 80.88M | 61.55M |
| Operating Income | -114.30M | -115.74M | -94.28M | -80.88M | -61.55M |
| Income Before Tax | -110.97M | -109.04M | -87.07M | -75.09M | -51.53M |
| Income Tax Expenses | 152.00K | 78.00K | 77.00K | 232.00K | -108.00K |
| Earnings from Continuing Operations | -111.12M | -109.12M | -87.15M | -75.32M | -51.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.12M | -109.12M | -87.15M | -75.32M | -51.42M |
| EBIT | -114.30M | -115.74M | -94.28M | -80.88M | -61.55M |
| EBITDA | -114.20M | -115.65M | -94.20M | -80.82M | -61.50M |
| EPS Basic | -0.76 | -0.75 | -0.60 | -0.52 | -0.36 |
| Normalized Basic EPS | -0.47 | -0.47 | -0.37 | -0.32 | -0.22 |
| EPS Diluted | -0.76 | -0.75 | -0.60 | -0.52 | -0.36 |
| Normalized Diluted EPS | -0.47 | -0.47 | -0.37 | -0.32 | -0.22 |
| Average Basic Shares Outstanding | 146.92M | 146.47M | 146.09M | 145.36M | 144.52M |
| Average Diluted Shares Outstanding | 146.92M | 146.47M | 146.09M | 145.36M | 144.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |